Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.66 |
| ▸ | LMNA | P02545 | 2/20 | 0.66 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL714235 | 1.00 | SMN1; SMN2 (0.66) | SMN1; SMN2LMNAMEN1KMT2ANPC1 | |
| SCHEMBL714234 | 1.00 | SMN1; SMN2 (0.66) | SMN1; SMN2LMNAMEN1KMT2ANPC1 | |
| SCHEMBL17260383 | 0.86 | SMN1; SMN2 (0.54) | SMN1; SMN2LMNAMEN1KMT2ANPC1 | |
| SCHEMBL17646176 | 0.86 | SMN1; SMN2 (0.54) | SMN1; SMN2LMNAMEN1KMT2ANPC1 | |
| SCHEMBL30317493 | 0.84 | MEN1 (0.53) | SMN1; SMN2LMNAMEN1KMT2ANPC1 | |
| Hydrochloric Acid SCHEMBL30317257 | 0.82 | MEN1 (0.51) | SMN1; SMN2LMNAMEN1KMT2ANPC1 | |
| SCHEMBL11202529 | 0.82 | SMN1; SMN2 (0.54) | SMN1; SMN2LMNAMEN1KMT2ANPC1 | |
| SCHEMBL11202526 | 0.82 | SMN1; SMN2 (0.54) | SMN1; SMN2LMNAMEN1KMT2ANPC1 | |
| SCHEMBL21635122 | 0.82 | SMN1; SMN2 (0.62) | SMN1; SMN2LMNAMEN1KMT2ANPC1 | |
| Hydrochloric Acid SCHEMBL16059705 | 0.81 | MEN1 (0.66) | SMN1; SMN2LMNAMEN1KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122094701-A | TLR3 binding bicyclic peptide ligands | — | 2026-05-26 | — | — | CN | claimed |
| US-12630588-B2 | Bicyclic peptide ligands specific for CD137 | BICYCLETX LIMITED (GB) | 2026-05-19 | — | — | US | claimed |
| US-12551535-B2 | Peptide pharmaceuticals for insulin resistance | MEDERIS DIABETES, LLC (US) | 2026-02-17 | — | — | US | claimed |
| US-20250325672-A1 | ANTI-INFECTIVE BICYCLIC PEPTIDE LIGANDS | BICYCLE TX LTD (GB) | 2025-10-23 | — | — | US | claimed |
| US-20250296959-A1 | B7-H3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF | MARIANA ONCOLOGY INC (US) | 2025-09-25 | — | — | US | claimed |
| WO-2025046244-A1 | TLR3 BINDING BICYCLIC PEPTIDE LIGANDS | BICYCLETX LIMITED (GB) | 2025-03-06 | — | — | WO | claimed |
| US-20250059236-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR CD137 | BICYCLETX LIMITED (GB) | 2025-02-20 | — | — | US | claimed |
| US-20240424062-A1 | PEPTIDE PHARMACEUTICALS FOR INSULIN RESISTANCE | MEDERIS DIABETES LLC (US) | 2024-12-26 | — | — | US | claimed |
| CN-118772242-A | CD137 specific bicyclic peptide ligands | 拜斯科技术开发有限公司 | 2024-10-15 | — | — | CN | claimed |
| US-12049520-B2 | Bicyclic peptide ligands specific for CD137 | BICYCLETX LIMITED (GB) | 2024-07-30 | — | — | US | claimed |
| EP-4093757-A1 | GIP/GLP1 CO-AGONIST COMPOUNDS | Eli Lilly and Company (US) | 2022-11-30 | — | — | EP | claimed |
| US-20220362345-A1 | PEPTIDE PHARMACEUTICALS FOR INSULIN RESISTANCE | MEDERIS DIABETES LLC (US) | 2022-11-17 | — | — | US | claimed |
| CN-115298207-A | GIP/GLP1 co-agonist compounds | 伊莱利利公司 | 2022-11-04 | — | — | CN | claimed |
| WO-2022195287-A9 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR TREM2 | BICYCLETX LIMITED (GB) | 2022-10-20 | — | — | WO | claimed |
| US-20220296726-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR TREM2 | BICYCLETX LIMITED (GB) | 2022-09-22 | — | — | US | claimed |
| WO-2022195287-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR TREM2 | BICYCLETX LIMITED (GB) | 2022-09-22 | — | — | WO | claimed |
| WO-2022177744-A1 | GIP/GLP1 DUAL AGONIST THERAPEUTIC METHODS | ELI LILLY AND COMPANY (US) | 2022-08-25 | — | — | WO | claimed |
| WO-2022148968-A1 | ANTI-INFECTIVE BICYCLIC PEPTIDE LIGANDS | BICYCLETX LIMITED (GB) | 2022-07-14 | — | — | WO | claimed |
| US-20220213145-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR CD137 | BICYCLETX LIMITED (GB) | 2022-07-07 | — | — | US | claimed |
| EP-3661948-B1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR CD137 | BICYCLETX LTD (GB) | 2022-06-01 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250325672-A1 | ANTI-INFECTIVE BICYCLIC PEPTIDE LIGANDS | ACE2, SARS1, TMPRSS2 | SMN1; SMN2 4777/4885LMNA 2785/4885MEN1 4373/4885 |
| US-12630588-B2 | Bicyclic peptide ligands specific for CD137 | PTMS, IL36G, HLA-A | SMN1; SMN2 4497/4885LMNA 452/4885MEN1 4195/4885 |
| US-12551535-B2 | Peptide pharmaceuticals for insulin resistance | IAPP, GLP1R, INSR | SMN1; SMN2 3910/4885LMNA 1547/4885MEN1 2329/4885 |
| US-20240424062-A1 | PEPTIDE PHARMACEUTICALS FOR INSULIN RESISTANCE | IAPP, GLP1R, PTMS | SMN1; SMN2 2670/4885LMNA 3205/4885MEN1 1876/4885 |
| US-20250296959-A1 | B7-H3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF | CD274, CD44, CD74 | SMN1; SMN2 3264/4885LMNA 3408/4885MEN1 640/4885 |
| US-20220296726-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR TREM2 | APP, TIMCC, ADM2 | SMN1; SMN2 1109/4885LMNA 1950/4885MEN1 2147/4885 |
| US-20250059236-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR CD137 | CD2BP2, CD40, SDC1 | SMN1; SMN2 3096/4885LMNA 2538/4885MEN1 3732/4885 |
| US-20220362345-A1 | PEPTIDE PHARMACEUTICALS FOR INSULIN RESISTANCE | IAPP, GLP1R, PTMS | SMN1; SMN2 2670/4885LMNA 3205/4885MEN1 1876/4885 |
| US-20220213145-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR CD137 | CD2BP2, CD40, SDC1 | SMN1; SMN2 3096/4885LMNA 2538/4885MEN1 3732/4885 |
| US-12049520-B2 | Bicyclic peptide ligands specific for CD137 | CD2BP2, CD40, SDC1 | SMN1; SMN2 3096/4885LMNA 2538/4885MEN1 3732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.